Overview
This study is a prospective, single-arm, single-center trial evaluating the efficacy of TACE combined with multimodal ablation, Tislelizumab, and lenvatinib in the treatment of unresectable primary liver cancer.
Description
This study aims to evaluate the efficacy and safety of multimodal ablation combined with Tislelizumab, lenvatinib, and TACE in the treatment of primary liver cancer. By comparing preoperative and postoperative immune markers, the study seeks to clarify the clinical value of multimodal ablation combined with systemic therapy and TACE in the management of primary liver cancer.
Eligibility
Inclusion Criteria:
- Age 30-90 yrs.
- Smartphone ownership
- Office SBP: ≥ 140 mm Hg
- ≤ 2 current anti-HTN meds
- Able to add or dose-increase at least 2 of the following classes of medications: ACE-I/ARB, diuretic, calcium channel blocker, beta-blocker, mineralocorticoid receptor antagonists (i.e., at least 2 classes are available for addition or dose- increases after excluding intolerant medications and medications currently at maximum dose)
- English or Spanish-speakers
Exclusion Criteria:
- Heart failure with reduced ejection fraction (EF \< 40%)
- ESRD (GFR \<15)
- Renal replacement therapy
- Pregnant
- Myocardial infarction or stroke within preceding 6 months
- Hospitalization for hypertensive emergency or malignant hypertension within preceding 6 months
- Prior solid organ transplantation
- At the clinical discretion of the investigators
- Enrolled in another clinical study
